Dostarlimab: First Approval
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
information about this Adis Drug Review can be found here.
(Jemperli™; GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1
(PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET
trial dostarlimab has recently been approved in the EU and USA for the treatment of adult patients with mismatch repair
deficient recurrent or advanced endometrial cancer. This article summarizes the milestones in the
development of dostarlimab leading to these first approvals.
© Springer Nature Switzerland AG 2021